Generation prozac. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Generation prozac. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Posit Aware. 1995 May/Jun;:18-9. Unique Identifier : AIDSLINE AIDS/95700408
Grodeck B

Abstract: About forty million Americans will experience a major depressive illness sometime during their lives. However, many will not seek treatment because of the social stigma attached to the disorder--depression is a sign of weakness or failure. For those that do seek treatment, many alternatives are available. The first generation of antidepressants, dubbed tricyclics (TCAs), provide relief from depression, but produce severe side effects. Monoamine oxidase inhibitors (MAOIs) allow more norepinephrine, dopamine, and serotonin to be produced--neurotransmitters linked to moods and sleep. They also exhibit many side effects. The newest drugs, selective serotonin reuptake inhibitors (SSRIs), relieve depression similar to the TCAs and MAOIs, but have a lower rate of unpleasant side effects. Prozac, within the SSRI family, is the most popular and most studied drug for the treatment of depression. Discovered by pharmaceutical company Eli Lilly and approved by the Food and Drug Administration (FDA) in 1987, prozac has been shown to work against obsessive-compulsive disorder, suicidal thoughts, and aggressive behavior--all of which can be symptoms of depression.
Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS Depression/COMPLICATIONS/*DRUG THERAPY/THERAPY Fluoxetine Human HIV Infections/COMPLICATIONS Psychotherapy NEWSLETTER ARTICLEKWDacquiredimmunodeficiencysyndrome/complicationsdepression/complications/KWDdrugtherapy/therapyfluoxetinehumanhivinfections/complicationspsychotherapynewsletterarticle
951230
M95C3188

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .